about
Disruption of amyloid plaques integrity affects the soluble oligomers content from Alzheimer disease brains.Soluble phospho-tau from Alzheimer's disease hippocampus drives microglial degeneration.Regional difference in inflammatory response to LPS-injection in the brain: role of microglia cell density.Defective lysosomal proteolysis and axonal transport are early pathogenic events that worsen with age leading to increased APP metabolism and synaptic Abeta in transgenic APP/PS1 hippocampus.Amyloid-β reduces the expression of neuronal FAIM-L, thereby shifting the inflammatory response mediated by TNFα from neuronal protection to death.Age-dependent accumulation of soluble amyloid beta (Abeta) oligomers reverses the neuroprotective effect of soluble amyloid precursor protein-alpha (sAPP(alpha)) by modulating phosphatidylinositol 3-kinase (PI3K)/Akt-GSK-3beta pathway in Alzheimer mIn vivo modification of Abeta plaque toxicity as a novel neuroprotective lithium-mediated therapy for Alzheimer's disease pathology.Extracellular amyloid-beta and cytotoxic glial activation induce significant entorhinal neuron loss in young PS1(M146L)/APP(751SL) mice.Early neuropathology of somatostatin/NPY GABAergic cells in the hippocampus of a PS1xAPP transgenic model of Alzheimer's disease.Calretinin interneurons are early targets of extracellular amyloid-beta pathology in PS1/AbetaPP Alzheimer mice hippocampus.Inter-individual variability in the expression of the mutated form of hPS1M146L determined the production of Abeta peptides in the PS1xAPP transgenic mice.Regulation of the phosphatase calcineurin by insulin-like growth factor I unveils a key role of astrocytes in Alzheimer's pathology.Inflammatory response in the hippocampus of PS1M146L/APP751SL mouse model of Alzheimer's disease: age-dependent switch in the microglial phenotype from alternative to classic.
P50
Q34654255-03056CF9-E6AF-4CB0-A591-0701119DF3FFQ37410147-A9D0FBBD-8C02-4CBD-AFCC-98754AD3905EQ39497904-8D369A93-A408-4ADB-BCCA-EB77BAB0CEFCQ42084165-DD57B427-540B-4A7A-AADA-80C409424427Q42642136-92BE4F28-CAD6-4DD3-B59F-22BD7013FC16Q42737591-73D14564-66FC-40F6-A042-A94182AAF433Q42762188-324AD95B-3A4B-4617-AC02-23CBA47B2DCBQ43297097-1FCFC1F1-738A-4451-9BC1-E557DCD2C0E8Q46791753-971B52D8-E499-430F-860E-9FB48E7F0A91Q48227001-899C2730-530F-4209-8C43-40A6CE3E20EFQ48300964-9903648E-ED26-481A-88B1-B92E022ACBF6Q48832254-2D3C0CC1-B212-4A39-AA7D-2C470A0CBCA9Q53297957-30CA9151-10E9-443E-875E-BC37707E64EA
P50
description
hulumtues
@sq
neurobiologiste
@fr
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Sebastian Jimenez
@ast
Sebastian Jimenez
@en
Sebastian Jimenez
@es
Sebastian Jimenez
@fr
Sebastian Jimenez
@nl
Sebastian Jimenez
@sl
type
label
Sebastian Jimenez
@ast
Sebastian Jimenez
@en
Sebastian Jimenez
@es
Sebastian Jimenez
@fr
Sebastian Jimenez
@nl
Sebastian Jimenez
@sl
prefLabel
Sebastian Jimenez
@ast
Sebastian Jimenez
@en
Sebastian Jimenez
@es
Sebastian Jimenez
@fr
Sebastian Jimenez
@nl
Sebastian Jimenez
@sl
P1053
K-6168-2017
P106
P21
P31
P3829
P496
0000-0002-9151-7587